Angel Lobo-Rojas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Angel Lobo-Rojas has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Artur Torres Cordeiro
Brazilian Center for Research in Energy and Materials (CNPEM)
6 shared publications - Bianca Nascimento Monteiro da Silva
Microbiológica Química e Farmacêutica, Rio de Janeiro, RJ, Brazil
3 shared publications - Carolina Bastos Pereira Ligiéro
Centro Brasileiro de Pesquisas Físicas 2 , Rua Dr. Xavier Sigaud, 150—Urca, 2290-180 Rio de Janeiro, RJ
3 shared publications - Jessica Do Nascimento Faria
Brazilian Biosciences National Laboratory, Brazilian Center for Research in Energy and Materials
3 shared publications - Michelle Fagundes Catelli
Brazilian Center for Research in Energy and Materials (CNPEM)
3 shared publications - Paulo Cesar Muniz de Lacerda Miranda
Universidade Estadual de Campinas (UNICAMP) image/svg+xml
3 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Elsevier in SSRN Electronic Journal
Selective dihydroquinazolinone inhibitors of Trypanosoma cruzi glucose-6-phosphate dehydrogenase uncover divergent enzymatic, cellular and in vivo activities
Glucose-6-phosphate dehydrogenase (G6PDH), the first enzyme of the oxidative pentose phosphate pathway, is essential for redox homeostasis in trypanosomatids, making it an attractive target. Here, we synthesized and evaluated a new series of non-steroidal dihydroquinazolinone derivatives against Trypanosoma cruzi G6PDH (TcG6PDH). Biochemical profiling revealed clear quantitative (QSAR) and structure–activity relationships (SAR); increasing halogen size on the aniline moiety enhanced enzymatic potency. The iodinated analogue 26 displayed submicromolar inhibition (IC50 = 0.12 µM) and nearly 200-fold selectivity over human G6PDH, though its enzymatic potency did not translate into antiparasitic efficacy, likely due to intracellular exposure limitations. Conversely, compound 17 exhibited the most balanced phenotypic profile, combining selective TcG6PDH inhibition with potent activity against epimastigotes and intracellular amastigotes (EC50 = 2.59 µM) without host cytotoxicity. In vitro ADME characterization of 17 revealed a potential solubility liability under neutral conditions but demonstrated high membrane permeability in both cellular and artificial barrier models. However, 17 failed to reduce parasitemia or tissue parasite burden in an acute murine model of Chagas disease. Pharmacological scaling using the well-stirred liver model reconciled this in vivo failure, identifying a critical combination of rapid microsomal metabolic clearance (t1/2 = 7 min in mouse) and high plasma protein binding (97.2%), which severely restricted the free, bioactive fraction (fu = 2.8%) in circulation. These findings expand the SAR and QSAR landscape of dihydroquinazolinone-based antitrypanosomal agents and demonstrate that future optimization must balance enzymatic potency with heterocyclic bioisosteric modifications to overcome metabolic susceptibility and plasma protein binding liabilities.
- 23 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSelective dihydroquinazolinone inhibitors of Trypanosoma cruzi glucose-6-phosphate dehydrogenase uncover divergent enzymatic, cellular and in vivo activities
Glucose-6-phosphate dehydrogenase (G6PDH), the first enzyme of the oxidative pentose phosphate pathway, is essential for redox homeostasis in trypanosomatids, making it an attractive target. Here, we synthesized and evaluated a new series of non-steroidal dihydroquinazolinone derivatives against Trypanosoma cruzi G6PDH (TcG6PDH). Biochemical profiling revealed clear quantitative (QSAR) and structure–activity relationships (SAR); increasing halogen size on the aniline moiety enhanced enzymatic potency. The iodinated analogue 26 displayed submicromolar inhibition (IC50 = 0.12 µM) and nearly 200-fold selectivity over human G6PDH, though its enzymatic potency did not translate into antiparasitic efficacy, likely due to intracellular exposure limitations. Conversely, compound 17 exhibited the most balanced phenotypic profile, combining selective TcG6PDH inhibition with potent activity against epimastigotes and intracellular amastigotes (EC50 = 2.59 µM) without host cytotoxicity. In vitro ADME characterization of 17 revealed a potential solubility liability under neutral conditions but demonstrated high membrane permeability in both cellular and artificial barrier models. However, 17 failed to reduce parasitemia or tissue parasite burden in an acute murine model of Chagas disease. Pharmacological scaling using the well-stirred liver model reconciled this in vivo failure, identifying a critical combination of rapid microsomal metabolic clearance (t1/2 = 7 min in mouse) and high plasma protein binding (97.2%), which severely restricted the free, bioactive fraction (fu = 2.8%) in circulation. These findings expand the SAR and QSAR landscape of dihydroquinazolinone-based antitrypanosomal agents and demonstrate that future optimization must balance enzymatic potency with heterocyclic bioisosteric modifications to overcome metabolic susceptibility and plasma protein binding liabilities.
- Open Access
- 4 March 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (3) , e0121025
Exploring T. cruzi IMPDH as a promising target through Chagas Box screening and AVN-944 inhibition
Chagas disease, caused by Trypanosoma cruzi , remains a leading cause of heart failure in Latin America, with current treatments limited to acute-phase efficacy, significant toxicity, and emerging resistance. Inosine monophosphate dehydrogenase (IMPDH) is an essential enzyme in guanine nucleotide salvage pathway and represents a promising alternative target. Here, we combined computational screening, biochemical and cell-based phenotypic assays that support T. cruzi IMPDH ( Tc IMPDH) as a druggable target and identify repurposing opportunities among clinical-stage inhibitors. Using Tanimoto similarity scoring against the library of 222 Chagas Box compounds, we identified TCMDC-143376 as uniquely similar to the clinical IMPDH inhibitors merimepodib and AVN-944. Phylogenetic analysis and multiple sequence alignment confirmed conservation of both catalytic and allosteric residues—drawn from T. foetus and T. brucei structures—within Tc IMPDH. Recombinant Tc IMPDH kinetics revealed Michaelis constants of 155 µM for IMP and 292 µM for NAD + . Biochemical IC 50 assays showed submicromolar inhibition by AVN-944 (0.20 µM), (S)-Merimepodib (0.21 µM), and (R)-Merimepodib (0.37 µM). In H9c2 cardiomyoblasts infected with intracellular amastigotes, AVN-944 achieved the lowest EC 50 (0.4 µM), outperforming benznidazole (EC 50 = 3.0 µM) and other inhibitors. Our findings support Tc IMPDH as a promising alternative drug target for Chagas disease and position AVN-944 as a compelling candidate to evaluate this therapeutic strategy in animal models.
- 4 March 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (3) , e0121025
Open AccessExploring T. cruzi IMPDH as a promising target through Chagas Box screening and AVN-944 inhibition
Chagas disease, caused by Trypanosoma cruzi , remains a leading cause of heart failure in Latin America, with current treatments limited to acute-phase efficacy, significant toxicity, and emerging resistance. Inosine monophosphate dehydrogenase (IMPDH) is an essential enzyme in guanine nucleotide salvage pathway and represents a promising alternative target. Here, we combined computational screening, biochemical and cell-based phenotypic assays that support T. cruzi IMPDH ( Tc IMPDH) as a druggable target and identify repurposing opportunities among clinical-stage inhibitors. Using Tanimoto similarity scoring against the library of 222 Chagas Box compounds, we identified TCMDC-143376 as uniquely similar to the clinical IMPDH inhibitors merimepodib and AVN-944. Phylogenetic analysis and multiple sequence alignment confirmed conservation of both catalytic and allosteric residues—drawn from T. foetus and T. brucei structures—within Tc IMPDH. Recombinant Tc IMPDH kinetics revealed Michaelis constants of 155 µM for IMP and 292 µM for NAD + . Biochemical IC 50 assays showed submicromolar inhibition by AVN-944 (0.20 µM), (S)-Merimepodib (0.21 µM), and (R)-Merimepodib (0.37 µM). In H9c2 cardiomyoblasts infected with intracellular amastigotes, AVN-944 achieved the lowest EC 50 (0.4 µM), outperforming benznidazole (EC 50 = 3.0 µM) and other inhibitors. Our findings support Tc IMPDH as a promising alternative drug target for Chagas disease and position AVN-944 as a compelling candidate to evaluate this therapeutic strategy in animal models.
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Tricarbonylmethane Scaffolds for Divergent Synthesis: Access to Aminomethylene-1,3-diketones and Dihydroquinazolinones
In this work, the synthesis of 55 tricarbonylmethane derivatives from dimedone, cyclohexane1,3-dione, indandione, and Meldrum’s acid using three complementary strategies is reported. In total, 10 α-hydroxymethylene-1,3-diones, 40 α-aryl/alkylaminomethylene-1,3-cycloalkanediones, and 5 dihydroquinazolin-5(6H)-ones were prepared, including 20 compounds described herein for the first time. Several members of these three families display relevant biological activities, including herbicidal activity (α-hydroxymethylene-1,3-diones), electron transport chain inhibition (α-aryl/alkylaminomethylene-1,3-cycloalkanediones), and inhibition of NADPH (nicotinamide adenine dinucleotide phosphate) production (dihydroquinazolin-5(6H)-ones). Particular attention was given to α-hydroxymethylene-1,3-diones as broad-spectrum intermediates, whose reactivity enabled access to α-aryl/alkylaminomethylene-1,3-cycloalkanediones and dihydroquinazolinones, highlighting their potential as entry points for diversity-oriented synthesis (DOS). The observed reactivity patterns suggest structural factors such as tricarbonylmethane acidity, tricarbonylmethane electrophilicity, nucleophile basicity, and steric hindrance effects control the reactions outcomes. Usually, DMF-DMA (N,N-dimethylformamide dimethyl acetal) provides a more general route to the α‑heteroatom-substituted methylenedione derivatives, but, depending on the acidity-basicity matching of tricarbonylmethane derivatives and nucleophiles, a multicomponent strategy may be applied. Commonly, although less general than the DMF-DMA sequence, a Steglich-type acylation protocol proved suitable for most of the studied compounds. Taken together, these results outline a flexible and substrate-dependent approach to tricarbonylmethane derivatives, while pointing to their broader potential for constructing structurally diverse heterocyclic frameworks relevant to organic synthesis and medicinal chemistry.
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Tricarbonylmethane Scaffolds for Divergent Synthesis: Access to Aminomethylene-1,3-diketones and Dihydroquinazolinones
In this work, the synthesis of 55 tricarbonylmethane derivatives from dimedone, cyclohexane1,3-dione, indandione, and Meldrum’s acid using three complementary strategies is reported. In total, 10 α-hydroxymethylene-1,3-diones, 40 α-aryl/alkylaminomethylene-1,3-cycloalkanediones, and 5 dihydroquinazolin-5(6H)-ones were prepared, including 20 compounds described herein for the first time. Several members of these three families display relevant biological activities, including herbicidal activity (α-hydroxymethylene-1,3-diones), electron transport chain inhibition (α-aryl/alkylaminomethylene-1,3-cycloalkanediones), and inhibition of NADPH (nicotinamide adenine dinucleotide phosphate) production (dihydroquinazolin-5(6H)-ones). Particular attention was given to α-hydroxymethylene-1,3-diones as broad-spectrum intermediates, whose reactivity enabled access to α-aryl/alkylaminomethylene-1,3-cycloalkanediones and dihydroquinazolinones, highlighting their potential as entry points for diversity-oriented synthesis (DOS). The observed reactivity patterns suggest structural factors such as tricarbonylmethane acidity, tricarbonylmethane electrophilicity, nucleophile basicity, and steric hindrance effects control the reactions outcomes. Usually, DMF-DMA (N,N-dimethylformamide dimethyl acetal) provides a more general route to the α‑heteroatom-substituted methylenedione derivatives, but, depending on the acidity-basicity matching of tricarbonylmethane derivatives and nucleophiles, a multicomponent strategy may be applied. Commonly, although less general than the DMF-DMA sequence, a Steglich-type acylation protocol proved suitable for most of the studied compounds. Taken together, these results outline a flexible and substrate-dependent approach to tricarbonylmethane derivatives, while pointing to their broader potential for constructing structurally diverse heterocyclic frameworks relevant to organic synthesis and medicinal chemistry.
- Open Access
Exploring T. cruzi IMPDH as a promising target through Chagas Box screening and AVN-944 inhibition
Chagas disease, caused by Trypanosoma cruzi , remains a leading cause of heart failure in Latin America, with current treatments limited to acute-phase efficacy, significant toxicity, and emerging resistance. Inosine monophosphate dehydrogenase (IMPDH) is an essential enzyme in guanine nucleotide salvage pathway and represents a promising alternative target. Here, we combined computational screening, biochemical and cell-based phenotypic assays that support T. cruzi IMPDH ( Tc IMPDH) as a druggable target and identify repurposing opportunities among clinical-stage inhibitors. Using Tanimoto similarity scoring against the library of 222 Chagas Box compounds, we identified TCMDC-143376 as uniquely similar to the clinical IMPDH inhibitors Merimepodib and AVN-944. Phylogenetic analysis and multiple sequence alignment confirmed conservation of both catalytic and allosteric residues—drawn from T. foetus and T. brucei structures—within Tc IMPDH. Recombinant Tc IMPDH kinetics revealed Michaelis constants of 155 µM for IMP and 292 µM for NAD⁺. Biochemical IC₅ ₀ assays showed submicromolar inhibition by AVN-944 (0.20 µM), (S)-Merimepodib (0.21 µM), and (R)-Merimepodib (0.37 µM). In H9c2 cardiomyoblasts infected with intracellular amastigotes, AVN-944 achieved the lowest EC₅ ₀ (0.4 µM) and highest selectivity index (SI > 100), outperforming benznidazole (EC₅ ₀ = 3.0 µM; SI = 13.4) and other inhibitors. Our findings support Tc IMPDH as a promising alternative drug target for Chagas disease and position AVN-944 as a compelling candidate to evaluate this therapeutic strategy in animal models.
Open AccessExploring T. cruzi IMPDH as a promising target through Chagas Box screening and AVN-944 inhibition
Chagas disease, caused by Trypanosoma cruzi , remains a leading cause of heart failure in Latin America, with current treatments limited to acute-phase efficacy, significant toxicity, and emerging resistance. Inosine monophosphate dehydrogenase (IMPDH) is an essential enzyme in guanine nucleotide salvage pathway and represents a promising alternative target. Here, we combined computational screening, biochemical and cell-based phenotypic assays that support T. cruzi IMPDH ( Tc IMPDH) as a druggable target and identify repurposing opportunities among clinical-stage inhibitors. Using Tanimoto similarity scoring against the library of 222 Chagas Box compounds, we identified TCMDC-143376 as uniquely similar to the clinical IMPDH inhibitors Merimepodib and AVN-944. Phylogenetic analysis and multiple sequence alignment confirmed conservation of both catalytic and allosteric residues—drawn from T. foetus and T. brucei structures—within Tc IMPDH. Recombinant Tc IMPDH kinetics revealed Michaelis constants of 155 µM for IMP and 292 µM for NAD⁺. Biochemical IC₅ ₀ assays showed submicromolar inhibition by AVN-944 (0.20 µM), (S)-Merimepodib (0.21 µM), and (R)-Merimepodib (0.37 µM). In H9c2 cardiomyoblasts infected with intracellular amastigotes, AVN-944 achieved the lowest EC₅ ₀ (0.4 µM) and highest selectivity index (SI > 100), outperforming benznidazole (EC₅ ₀ = 3.0 µM; SI = 13.4) and other inhibitors. Our findings support Tc IMPDH as a promising alternative drug target for Chagas disease and position AVN-944 as a compelling candidate to evaluate this therapeutic strategy in animal models.
- Open Access
- 13 December 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (2) , 108080
Inhibition of L-threonine dehydrogenase from Trypanosoma cruzi reduces glycine and acetate production and interferes with parasite growth and viability
- 13 December 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (2) , 108080
Open AccessInhibition of L-threonine dehydrogenase from Trypanosoma cruzi reduces glycine and acetate production and interferes with parasite growth and viability
- Open Access
Consumption of Galactose by Trypanosoma cruzi Epimastigotes Generates Resistance against Oxidative Stress
In this study, we demonstrate that Trypanosoma cruzi epimastigotes previously grown in LIT medium supplemented with 20 mM galactose and exposed to sub-lethal concentrations of hydrogen peroxide (100 μM) showed two-fold and five-fold viability when compared to epimastigotes grown in LIT medium supplemented with two different glucose concentrations (20 mM and 1.5 mM), respectively. Similar results were obtained when exposing epimastigotes from all treatments to methylene blue 30 μM. Additionally, through differential centrifugation and the selective permeabilization of cellular membranes with digitonin, we found that phosphoglucomutase activity (a key enzyme in galactose metabolism) occurs predominantly within the cytosolic compartment. Furthermore, after partially permeabilizing epimastigotes with digitonin (0.025 mg × mg−1 of protein), intact glycosomes treated with 20 mM galactose released a higher hexose phosphate concentration to the cytosol in the form of glucose-1-phosphate, when compared to intact glycosomes treated with 20 mM glucose, which predominantly released glucose-6-phosphate. These results shine a light on T. cruzi’s galactose metabolism and its interplay with mechanisms that enable resistance to oxidative stress.
Open AccessConsumption of Galactose by Trypanosoma cruzi Epimastigotes Generates Resistance against Oxidative Stress
In this study, we demonstrate that Trypanosoma cruzi epimastigotes previously grown in LIT medium supplemented with 20 mM galactose and exposed to sub-lethal concentrations of hydrogen peroxide (100 μM) showed two-fold and five-fold viability when compared to epimastigotes grown in LIT medium supplemented with two different glucose concentrations (20 mM and 1.5 mM), respectively. Similar results were obtained when exposing epimastigotes from all treatments to methylene blue 30 μM. Additionally, through differential centrifugation and the selective permeabilization of cellular membranes with digitonin, we found that phosphoglucomutase activity (a key enzyme in galactose metabolism) occurs predominantly within the cytosolic compartment. Furthermore, after partially permeabilizing epimastigotes with digitonin (0.025 mg × mg−1 of protein), intact glycosomes treated with 20 mM galactose released a higher hexose phosphate concentration to the cytosol in the form of glucose-1-phosphate, when compared to intact glycosomes treated with 20 mM glucose, which predominantly released glucose-6-phosphate. These results shine a light on T. cruzi’s galactose metabolism and its interplay with mechanisms that enable resistance to oxidative stress.
- 1 May 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1866 (5-6) , 651-660
Enolase from Trypanosoma cruzi is inhibited by its interaction with metallocarboxypeptidase-1 and a putative acireductone dioxygenase
- 1 May 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1866 (5-6) , 651-660
Enolase from Trypanosoma cruzi is inhibited by its interaction with metallocarboxypeptidase-1 and a putative acireductone dioxygenase
- 1 October 2016
- Published by Elsevier in Parasitology International
- Vol. 65 (5) , 472-482
Trypanosoma cruzi contains two galactokinases; molecular and biochemical characterization
- 1 October 2016
- Published by Elsevier in Parasitology International
- Vol. 65 (5) , 472-482
Trypanosoma cruzi contains two galactokinases; molecular and biochemical characterization